Search Results

Evelo Biosciences, Inc. today announced its second quarter 2023 financial results and recent business highlights.

Evelo Biosciences, Inc. today announced updates to its clinical programs.

Evelo Biosciences, Inc. today announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company’s common stock.

Evelo Biosciences, Inc. (Nasdaq:EVLO) (“Evelo” or the “Company”), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced top-line results from its Phase 2 clinical study with EDP2939 in moderate psoriasis.

Evelo Biosciences, Inc. today announced that it has entered into a securities purchase agreement with investors in a private placement to sell 11,025,334 shares of its common stock (the “Shares”) at a purchase price of $2.31 per share.

Evelo Biosciences, Inc. today announces that it closed the previously announced private placement, resulting in gross proceeds of approximately $25.5 million from the sale of 11,025,334 shares of its common stock at a purchase price of $2.31 per share.

Evelo Biosciences, Inc. today reported financial results and business highlights for the fourth quarter and full year 2022.

Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis (SINTAX) today announced updates to its clinical pipeline as well as business updates.

In an SEC filing, the biotech launched by Flagship Pioneering said there was no viable alternative to dissolution as its cash ran out and anti-inflammatory assets failed to achieve clinical success.

Evelo Biosciences, Inc. announced that Mark Plinio, J.D., Chief Commercial Officer will participate in a dermatology panel at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 12:50 p.m. ET.